FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3211206475> ?p ?o ?g. }

• W3211206475 endingPage "44" @default.
• W3211206475 startingPage "33" @default.
• W3211206475 abstract "The P2X4 receptor is a ligand-gated ion channel activated by extracellular ATP. P2X4 activity is associated with neuropathic pain, vasodilation, and pulmonary secretion and is therefore of therapeutic interest. The structure-activity relationship of P2X4 antagonists is poorly understood. Here we elucidate the structure-activity of 5-(3-bromophenyl)-1,3-dihydro-2H-benzofuro[3,2-e]-1,4-diazepin-2-one (5-BDBD) at human P2X4 by combining pharmacology, electrophysiology, molecular modeling, and medicinal chemistry. 5-BDBD antagonized P2X4 in a noncompetitive manner but lacked effect at human P2X2. Molecular modeling and site-directed mutagenesis suggested an allosteric binding site for 5-BDBD located between two subunits in the body region of P2X4, with M109, F178, Y300, and I312 on one subunit and R301 on the neighboring subunit as key residues involved in antagonist binding. The bromine group of 5-BDBD was redundant for the antagonist activity of 5-BDBD, although an interaction between the carbonyl group of 5-BDBD and R301 in P2X4 was associated with 5-BDBD activity. 5-BDBD could inhibit the closed channel but poorly inhibited the channel in the open/desensitizing state. We hypothesize that this is due to constriction of the allosteric site after transition from closed to open channel state. We propose that M109, F178, Y300, R301, and I312 are key residues for 5-BDBD binding; provide a structural explanation of how they contribute to 5-BDBD antagonism; and highlight that the limited action of 5-BDBD on open versus closed channels is due to a conformational change in the allosteric site. SIGNIFICANCE STATEMENT: Activity of P2X4 receptor is associated with neuropathic pain, inflammation, and vasodilatation. Molecular information regarding small-molecule interaction with P2X4 is very limited. Here, this study provides a structural explanation for the action of the small-molecule antagonist 5-BDBD at the human P2X4 receptor." @default.
• W3211206475 created "2021-11-08" @default.
• W3211206475 creator A5008744647 @default.
• W3211206475 creator A5019069268 @default.
• W3211206475 creator A5024900800 @default.
• W3211206475 creator A5034761384 @default.
• W3211206475 creator A5037866390 @default.
• W3211206475 creator A5044134695 @default.
• W3211206475 creator A5044462563 @default.
• W3211206475 creator A5064819520 @default.
• W3211206475 date "2021-10-30" @default.
• W3211206475 modified "2023-10-02" @default.
• W3211206475 title "Structural Basis of the Negative Allosteric Modulation of 5-BDBD at Human P2X4 Receptors" @default.
• W3211206475 cites W1507887256 @default.
• W3211206475 cites W1984025105 @default.
• W3211206475 cites W2007435066 @default.
• W3211206475 cites W2036402933 @default.
• W3211206475 cites W2064309662 @default.
• W3211206475 cites W2065283382 @default.
• W3211206475 cites W2078336096 @default.
• W3211206475 cites W2089435101 @default.
• W3211206475 cites W2090241673 @default.
• W3211206475 cites W2090527768 @default.
• W3211206475 cites W2100125011 @default.
• W3211206475 cites W2103591844 @default.
• W3211206475 cites W2148640061 @default.
• W3211206475 cites W2160864523 @default.
• W3211206475 cites W2332712348 @default.
• W3211206475 cites W2439976878 @default.
• W3211206475 cites W2513150856 @default.
• W3211206475 cites W2550534389 @default.
• W3211206475 cites W2604255566 @default.
• W3211206475 cites W2614066293 @default.
• W3211206475 cites W2615936384 @default.
• W3211206475 cites W2767041448 @default.
• W3211206475 cites W2771328536 @default.
• W3211206475 cites W2780208148 @default.
• W3211206475 cites W2791419854 @default.
• W3211206475 cites W2872677064 @default.
• W3211206475 cites W2897079566 @default.
• W3211206475 cites W2938159790 @default.
• W3211206475 cites W2943505387 @default.
• W3211206475 cites W2954247725 @default.
• W3211206475 cites W2980529659 @default.
• W3211206475 cites W2982201100 @default.
• W3211206475 cites W2999874542 @default.
• W3211206475 cites W3004055520 @default.
• W3211206475 cites W3042566941 @default.
• W3211206475 cites W3097463406 @default.
• W3211206475 doi "https://doi.org/10.1124/molpharm.121.000402" @default.
• W3211206475 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34718224" @default.
• W3211206475 hasPublicationYear "2021" @default.
• W3211206475 type Work @default.
• W3211206475 sameAs 3211206475 @default.
• W3211206475 citedByCount "11" @default.
• W3211206475 countsByYear W32112064752022 @default.
• W3211206475 countsByYear W32112064752023 @default.
• W3211206475 crossrefType "journal-article" @default.
• W3211206475 hasAuthorship W3211206475A5008744647 @default.
• W3211206475 hasAuthorship W3211206475A5019069268 @default.
• W3211206475 hasAuthorship W3211206475A5024900800 @default.
• W3211206475 hasAuthorship W3211206475A5034761384 @default.
• W3211206475 hasAuthorship W3211206475A5037866390 @default.
• W3211206475 hasAuthorship W3211206475A5044134695 @default.
• W3211206475 hasAuthorship W3211206475A5044462563 @default.
• W3211206475 hasAuthorship W3211206475A5064819520 @default.
• W3211206475 hasBestOaLocation W32112064751 @default.
• W3211206475 hasConcept C104292427 @default.
• W3211206475 hasConcept C104317684 @default.
• W3211206475 hasConcept C107824862 @default.
• W3211206475 hasConcept C12554922 @default.
• W3211206475 hasConcept C16318435 @default.
• W3211206475 hasConcept C166342909 @default.
• W3211206475 hasConcept C170493617 @default.
• W3211206475 hasConcept C185592680 @default.
• W3211206475 hasConcept C2776885963 @default.
• W3211206475 hasConcept C501734568 @default.
• W3211206475 hasConcept C55493867 @default.
• W3211206475 hasConcept C71240020 @default.
• W3211206475 hasConcept C86803240 @default.
• W3211206475 hasConcept C98274493 @default.
• W3211206475 hasConceptScore W3211206475C104292427 @default.
• W3211206475 hasConceptScore W3211206475C104317684 @default.
• W3211206475 hasConceptScore W3211206475C107824862 @default.
• W3211206475 hasConceptScore W3211206475C12554922 @default.
• W3211206475 hasConceptScore W3211206475C16318435 @default.
• W3211206475 hasConceptScore W3211206475C166342909 @default.
• W3211206475 hasConceptScore W3211206475C170493617 @default.
• W3211206475 hasConceptScore W3211206475C185592680 @default.
• W3211206475 hasConceptScore W3211206475C2776885963 @default.
• W3211206475 hasConceptScore W3211206475C501734568 @default.
• W3211206475 hasConceptScore W3211206475C55493867 @default.
• W3211206475 hasConceptScore W3211206475C71240020 @default.
• W3211206475 hasConceptScore W3211206475C86803240 @default.
• W3211206475 hasConceptScore W3211206475C98274493 @default.
• W3211206475 hasIssue "1" @default.
• W3211206475 hasLocation W32112064751 @default.
• W3211206475 hasLocation W32112064752 @default.

• next